A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

NCT04250246 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

184

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Non Small Cell Lung Cancer

Interventions

DRUG: Ipilimumab plus nivolumab plus guadecitabine
DRUG: Ipilimumab plus nivolumab

Sponsor

Italian Network for Tumor Biotherapy Foundation

Collaborators

[object Object]
[object Object]